Literature DB >> 15328837

[Validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis--assessment questionnaire 40 (ALSAQ-40)].

Takuhiro Yamaguchi1, Sadayoshi Ohbu, Mari Saito, Yoichi Ito, Fumio Moriwaka, Kunio Tashiro, Yasuo Ohashi, Shun-ichi Fukuhara.   

Abstract

We studied validity and clinical applicability of the Japanese version of amyotrophic lateral sclerosis (ALS) assessment questionnaire 40 (ALSAQ-40). The original version contains forty questions measuring five areas (domains) of health status: Physical Mobility, ADL/Independence, Eating and Drinking, Communication and Emotional Functioning. Data were obtained from 39 ALS patients and from their physicians at 15 centers in Japan. Patients completed the ALSAQ-40 and the SF-36, and provided information on their age and their status of ventilator use. Their physicians provided information on the date of diagnosis, type of disease and clinical characteristics, and ALSFRS-R. The patients' average age was 58.5 years, and 64% were men. The mean duration since diagnosis was 39.1 months. Forty four percent were classical ALS patients and 46% were receiving a respiratory intervention. Although there was much heterogeneity, the scores for Physical Mobility and ADL/Independence were higher(indicating worse health status)than the scores for the other domains. Item-scale correlations were strong, except for the item "felt embarrassed in social situations" in the Emotional Functioning domain. All the domains had very high internal consistency: Cronbach's alphas ranged 0.95 to 0.97. With regard to the cluster structure of the forty items, the Eating and Drinking domain and the Communication clustered together. The reason might be that the former consisted of only three items and both domains measure bulbar symptoms. Domain scores correlated significantly with scores of related dimensions in the SF-36 and ALSFRS-R, and did not correlate strongly with unrelated domains. The five items of the ALSAQ-5 correlated with all five domain scores on the ALSAQ-40. These results should be interpreted with caution because we analyzed together data from ALS patients with various characteristics. In conclusion, although we may need to add and remove some items and modify the wording of others, the Japanese version of the ALSAQ-40 had high validity and is likely to be useful in evaluating of QOL in ALS patients. Whether the ALSAQ-5 can be used in place of the ALSAQ-40 is a matter for further study.

Entities:  

Mesh:

Year:  2004        PMID: 15328837

Source DB:  PubMed          Journal:  No To Shinkei        ISSN: 0006-8969


  5 in total

1.  Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Haruhiko Banno; Keisuke Suzuki; Noriaki Suga; Fumiaki Tanaka; Gen Sobue
Journal:  J Neurol       Date:  2011-09-28       Impact factor: 4.849

2.  Efficacy and safety of leuprorelin acetate for subjects with spinal and bulbar muscular atrophy: pooled analyses of two randomized-controlled trials.

Authors:  Atsushi Hashizume; Masahisa Katsuno; Keisuke Suzuki; Haruhiko Banno; Yu Takeuchi; Motoshi Kawashima; Noriaki Suga; Tomoo Mano; Amane Araki; Yasuhiro Hijikata; Akihiro Hirakawa; Gen Sobue
Journal:  J Neurol       Date:  2019-03-07       Impact factor: 4.849

3.  Impact and characteristics of quality of life in Japanese patients with multiple sclerosis.

Authors:  Hiromi Kikuchi; Nobuhiro Mifune; Masaaki Niino; Sadayoshi Ohbu; Jun-ichi Kira; Tatsuo Kohriyama; Kohei Ota; Masami Tanaka; Hirofumi Ochi; Shunya Nakane; Masaji Maezawa; Seiji Kikuchi
Journal:  Qual Life Res       Date:  2010-08-11       Impact factor: 4.147

4.  Self perceived emotional functioning of spanish patients with amyotrophic lateral sclerosis: a longitudinal study.

Authors:  Jesús S Mora; Teresa Salas; María L Fajardo; Lourdes Iváñez; Francisco Rodríguez-Santos
Journal:  Front Psychol       Date:  2013-01-08

5.  Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients.

Authors:  Koji Abe; Yasuto Itoyama; Gen Sobue; Shoji Tsuji; Masashi Aoki; Manabu Doyu; Chikuma Hamada; Kazuoki Kondo; Takatomo Yoneoka; Makoto Akimoto; Hiide Yoshino
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2014-10-06       Impact factor: 4.092

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.